Abdominal Swelling (Ascites) in Pancreatic Cancer
Ascites (pronounced aye-site-eez) is the medical name for a build up of fluid in the tummy (abdomen). If the ascites is caused by cancer it can be called malignant ascites.
Summary: Ascites is a common complication in advanced pancreatic cancer, characterized by fluid buildup in the abdomen. This article explains causes, symptoms, diagnosis, treatment options, prognosis, and current research. It addresses patient concerns, including “how long can someone live with ascites from pancreatic cancer” and “excess abdominal fluid.”
What is Ascites in Pancreatic Cancer?
Ascites (pronounced aye-site-eez) refers to a buildup of fluid in the abdominal cavity. In pancreatic cancer, this condition is often called malignant ascites. Fluid accumulates between the layers of the peritoneum, the membrane lining the abdomen, causing swelling, discomfort, and digestive pressure.
Heather developed ascites during the last two or three weeks of her life. While doctors in Canada signaled it was the final stages of the disease, our oncologist at Johns Hopkins wanted to rule out other causes, such as a blockage. Testing was completed and confirmed it was not due to a blockage. Watching Heather’s stomach swell and become uncomfortably tight was a traumatic experience, and ascites remains one of the most distressing complications of pancreatic cancer.
Causes of Ascites in Pancreatic Cancer
Malignant ascites can be caused by multiple factors, including:
- Irritation of the Peritoneal Lining: Cancer cells can irritate and inflame the peritoneum, leading to fluid production.
- Lymphatic Blockage: Cancerous growths may obstruct lymph glands, impairing fluid drainage.
- Liver Metastasis: When cancer spreads to the liver, it increases pressure in abdominal blood vessels, contributing to fluid accumulation.
- Reduced Blood Protein Production: Pancreatic cancer can impair liver function, decreasing protein levels like albumin, which helps maintain fluid balance.
Symptoms and Diagnosis
Common Symptoms
People living with pancreatic cancer who develop ascites may experience:
- Abdominal swelling and tightness
- Rapid weight gain
- Shortness of breath
- Loss of appetite
- Nausea and indigestion
- Fatigue
Diagnostic Procedures
Diagnosing ascites involves several steps:
- Physical Examination: Doctors may detect fluid buildup during an abdominal check.
- Imaging Tests: Ultrasounds and CT scans confirm the presence and extent of fluid.
- Blood Tests: These evaluate protein levels and liver function.
- Paracentesis: A thin needle or catheter is used to extract fluid from the abdomen for analysis. This helps identify the cause, check for infections, and examine fluid composition.
Treatment Options
Management of ascites in pancreatic cancer patients focuses on symptom relief:
1. Paracentesis: A procedure to remove the fluid from the abdome.
2. Diuretics: Medications like spironolactone help reduce fluid buildup by promoting its removal through urine.
3. Targeted Therapies: Treatments such as bevacizumab (an anti-angiogenic agent) may reduce fluid accumulation by targeting specific cancer pathways.
4. Immunotherapies: These emerging treatments show promise in managing malignant ascites.
5. Concentrated Ascites Reinfusion Therapy (CART): This technique filters and reinfuses ascitic fluid to alleviate symptoms.
Personal Experience with Heather
Paracentesis is the most common treatment. Initially, it’s a quick in-and-out procedure to drain excess fluid. However, when the fluid inevitably returns, patients are often given a permanent drain to manage the fluid at home for their comfort.
Initially, the staff at Health Sciences and the oncology team did not provide any instructions after the permanent drain was placed, and the fluid was drained continuously.
What was not communciated was that this fluid contains multiple components, including protein albumin, which can be significantly depleted during drainage, further weakening the patient.
Prognosis and Quality of Life
The development of ascites in pancreatic cancer patients often indicates advanced disease and is associated with a poor prognosis. Studies have shown that median survival after the onset of ascites is approximately 1.8 to 2 months.
Despite this, proactive symptom management and emerging treatments can improve comfort and extend quality of life.
Current Research and Future Directions
Exciting advancements in treating malignant ascites aim to improve symptom relief and survival rates. Areas of research include:
- Novel Diagnostic Biomarkers: Identifying specific markers in ascitic fluid for better diagnosis and treatment planning.
- Immunotherapy Approaches: Therapies using immune cells or checkpoint inhibitors to target cancer cells.
- Targeted Molecular Therapies: Drugs that inhibit cancer growth pathways.
- Improved Palliative Care: Strategies to enhance comfort and quality of life.
Bevacizumab and Other Targeted Agents
- Bevacizumab: This anti-angiogenic drug has shown potential in reducing fluid buildup. Intraperitoneal administration extended the time between paracentesis procedures in some studies.
- Apatinib with Gemcitabine: This combination increased progression-free survival and reduced the frequency of paracentesis in some cases.
- NK4 Therapy: Targeting specific growth factor receptors, NK4 suppressed fluid buildup in animal models.
Immunotherapy
Immunotherapy has emerged as a promising avenue for treating malignant ascites:
- Intraperitoneal nivolumab reduced fluid buildup and cancer cell presence in ascitic fluid.
- CART improved symptoms, enhanced immune response, and enabled chemotherapy.
- Combining NK cells with PD-1 inhibitors activated immune cells and targeted cancer effectively.
Novel Delivery Methods
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)
PIPAC using nanoparticle albumin-bound paclitaxel (NAB-PTX) has shown positive responses in 35% of patients with peritoneal metastases, including those from pancreatic cancer.
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Laparoscopic HIPEC reported complete resolution of ascites in 94% of patients with peritoneal carcinomatosis.
Combination Therapies
Research is exploring various combination approaches:
• Intraperitoneal paclitaxel combined with intravenous nab-paclitaxel and gemcitabine increased overall survival, though peritoneal recurrence occurred in 75% of patients.
• Intraperitoneal cisplatin with intravenous gemcitabine and regional hypothermia showed partial response in 13 out of 29 patients, with a median overall survival of 195 days.
Oncolytic Therapy
Intraperitoneal oncolytic therapy has shown positive ascites control in 8 out of 13 patients in one study.
These advancements offer new hope for managing malignant ascites in pancreatic cancer patients. However, it’s important to note that many of these treatments are still in experimental stages and require further research to establish their efficacy and safety in larger patient populations.
